<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00244959</url>
  </required_header>
  <id_info>
    <org_study_id>J0365 CDR0000446285</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0365</secondary_id>
    <secondary_id>JHOC-SKCCC-J0365</secondary_id>
    <nct_id>NCT00244959</nct_id>
  </id_info>
  <brief_title>Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer</brief_title>
  <official_title>Surrogate Markers of Response: A Phase II Study of Changes in Breast Density Among Postmenopausal Women Receiving Adjuvant Anastrozole Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using&#xD;
      anastrozole may fight breast cancer by lowering the amount of estrogen the body makes.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how anastrozole effects postmenopausal women who&#xD;
      have undergone surgery for ductal carcinoma in situ or stage I, stage II, or stage III breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the 12-month change in breast density in postmenopausal women with ductal&#xD;
           carcinoma in situ (DCIS) or stage I-III breast cancer treated with adjuvant anastrozole.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the change in estrone sulfate levels in patients treated with this drug.&#xD;
&#xD;
        -  Correlate the change in breast density with the change in circulating estrone sulfate&#xD;
           levels in patients treated with this drug.&#xD;
&#xD;
        -  Determine the frequency of polymorphisms in aromatase (CYP19) and evaluate the&#xD;
           relationship between wild-type aromatase enzyme with change in breast density and change&#xD;
           in estrone sulfate levels in patients treated with this drug.&#xD;
&#xD;
        -  Determine the 12-month change in bone density, and correlate it with the change in&#xD;
           circulating estrone sulfate levels in patients treated with this drug.&#xD;
&#xD;
        -  Correlate the reversal of hypermethylation with change in circulating estrone sulfate&#xD;
           levels and breast density in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a pilot study. Patients are stratified according to concurrent&#xD;
      bisphosphonate use (yes vs no).&#xD;
&#xD;
      Patients receive oral anastrozole once daily for up to 12 months in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in breast density after 12 months of treatment</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hormone levels after 12 months of treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between change in breast density with change in hormone levels after 12 months of treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between the frequency of aromatase polymorphisms with changes in breast density and hormone levels after 12 months of treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between change in bone density with change in hormone levels after 12 months of treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between tissue methylation with changes in breast density and hormone levels after 12 months of treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anastrozole (1mg, orally, daily) for 12 months as adjuvant therapy for breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>1 mg orally daily for 12 months</description>
    <arm_group_label>Anastrozole</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <description>treatment received after breast cancer surgery</description>
    <arm_group_label>Anastrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer meeting 1 of the following criteria:&#xD;
&#xD;
               -  Ductal carcinoma in situ (DCIS)&#xD;
&#xD;
               -  Invasive carcinoma&#xD;
&#xD;
                    -  Stage I-III disease&#xD;
&#xD;
          -  Must have undergone breast cancer surgery within the past 6 months, including any of&#xD;
             the following:&#xD;
&#xD;
               -  Mastectomy or lumpectomy with or without radiation&#xD;
&#xD;
               -  Sentinel node and/or axillary node dissection&#xD;
&#xD;
               -  Re-excision of lumpectomy margins&#xD;
&#xD;
          -  Intact contralateral breast&#xD;
&#xD;
               -  No prior radiation therapy or mastectomy&#xD;
&#xD;
               -  Prior biopsies allowed&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen and/or progesterone receptor-positive tumor by immunohistochemical&#xD;
                  staining&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Postmenopausal, defined as 1 of the following:&#xD;
&#xD;
               -  At least 60 years of age&#xD;
&#xD;
               -  Less than 60 years of age and amenorrheic ≥ 12 months prior to study entry&#xD;
&#xD;
               -  Less than 60 years of age, amenorrheic for &lt; 12 months prior to day 1, and&#xD;
                  luteinizing hormone (LH) and follicle stimulating hormone (FSH) values within&#xD;
                  postmenopausal range&#xD;
&#xD;
               -  Less than 60 years of age, without a uterus, and LH and FSH values within&#xD;
                  postmenopausal range&#xD;
&#xD;
               -  Underwent prior bilateral oophorectomy&#xD;
&#xD;
               -  Underwent prior radiation castration AND amenorrheic for ≥ 6 months&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior or concurrent adjuvant chemotherapy for breast cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior aromatase inhibitor&#xD;
&#xD;
          -  At least 6 weeks since prior and no concurrent tamoxifen&#xD;
&#xD;
          -  At least 6 weeks since prior and no concurrent hormone replacement therapy&#xD;
&#xD;
               -  Concurrent low-dose, local vaginal estrogen in the form of either a conjugated&#xD;
                  estrogen ring or other similar product (e.g., Estring® or Vagifem®) allowed&#xD;
&#xD;
          -  At least 6 weeks since prior and no other concurrent selective estrogen receptor&#xD;
             modulators (e.g., raloxifene)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No contralateral breast implant&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed at the discretion of the treating oncologist&#xD;
&#xD;
          -  No concurrent consumption of soy supplements&#xD;
&#xD;
               -  Concurrent routine dietary consumption of soy-containing foods allowed&#xD;
&#xD;
          -  No other concurrent investigational or commercial drugs or therapies for the treatment&#xD;
             of DCIS or invasive breast cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vered Stearns, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers PP, Wright LA, Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer E, Skaar TC, Davidson NE, Stearns V. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila). 2011 Dec;4(12):1993-2001. doi: 10.1158/1940-6207.CAPR-11-0154. Epub 2011 Sep 1.</citation>
    <PMID>21885816</PMID>
  </results_reference>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>October 25, 2005</study_first_submitted>
  <study_first_submitted_qc>October 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2005</study_first_posted>
  <last_update_submitted>March 18, 2013</last_update_submitted>
  <last_update_submitted_qc>March 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>breast cancer in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

